60186-26-7 Usage
Uses
Used in Pharmaceutical Industry:
2,3-Pyridinediamine,6-fluoro-(9CI) is used as a building block in the synthesis of new drugs for its potential to enhance the properties of pharmaceutical compounds. The presence of a fluorine atom can improve the pharmacokinetic and pharmacodynamic profiles of the resulting drugs, making them more effective and safer for use.
Used in Agrochemical Industry:
2,3-Pyridinediamine,6-fluoro-(9CI) is used as a building block in the development of new pesticides. The incorporation of a fluorine atom can enhance the biological activity and selectivity of the resulting agrochemicals, leading to more effective and environmentally friendly products.
Used in Organic Synthesis:
2,3-Pyridinediamine,6-fluoro-(9CI) is used as a versatile intermediate in organic synthesis for the preparation of various biologically active compounds. Its unique structure and fluorinated nature make it a valuable component in the synthesis of complex organic molecules with potential applications in various fields.
Used in Research and Development:
2,3-Pyridinediamine,6-fluoro-(9CI) is used as a research compound to explore its chemical and physical properties. Further studies are needed to fully understand its potential uses and properties, which could lead to the discovery of new applications in various industries.
Check Digit Verification of cas no
The CAS Registry Mumber 60186-26-7 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 6,0,1,8 and 6 respectively; the second part has 2 digits, 2 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 60186-26:
(7*6)+(6*0)+(5*1)+(4*8)+(3*6)+(2*2)+(1*6)=107
107 % 10 = 7
So 60186-26-7 is a valid CAS Registry Number.
60186-26-7Relevant academic research and scientific papers
SPECIFIC INHIBITORS OF METHIONYL-TRNA SYNTHETASE
-
Paragraph 0094, (2016/03/13)
The present disclosure is generally directed to compositions useful in the inhibition of MetRS and methods for treating diseases that are ameliorated by the inhibition of MetRS.
